Clinical Trial Update: Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pembrolizumab with involved-site radiation therapy for early-stage relapsed or primary refractory Hodgkin lymphoma. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING